Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16203226 | 0.89 | PDE1B (0.46) | PDE1BKCNH2 | |
| SCHEMBL9980444 | 0.82 | PDE1B (0.45) | PDE1BKCNH2PDE5APDE1APDE1C | |
| SCHEMBL9980490 | 0.79 | PDE5A (0.47) | PDE1BKCNH2PDE5A | |
| SCHEMBL14951828 | 0.75 | JAK3 (0.31) | — | |
| SCHEMBL22075277 | 0.75 | PDE1B (0.49) | PDE1BKCNH2 | |
| SCHEMBL22075278 | 0.74 | KCNH2 (0.43) | PDE1BKCNH2 | |
| SCHEMBL9980488 | 0.72 | PDE1B (0.56) | PDE1BPDE5A | |
| SCHEMBL30579138 | 0.72 | PDE1B (0.46) | PDE1BKCNH2 | |
| SCHEMBL9980553 | 0.70 | MET (0.39) | — | |
| SCHEMBL24138327 | 0.66 | PDE5A (0.54) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575462-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2575462-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| CN-103153062-A | Heterocyclic compounds and their use | INTELLIKINE INC | 2013-06-12 | — | — | CN | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | MTOR, PIK3CA, AKT1 | PDE1B 529/4885KCNH2 4083/4885PDE5A 1272/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PDE1B 986/4885KCNH2 4225/4885PDE5A 1324/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PDE1B 576/4885KCNH2 4569/4885PDE5A 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.